Der forventes øgede aktiviteter i relation til leveringen af oplysninger til patientorganisationer og de berørte parter (forskere, fagfolk inden for sundhedssektoren og sponsorer), herunder offentliggørelse af sammendrag af udtalelsen på tidspunktet for vedtagelsen af Europa - Kommissionens beslutning.
Increase in number of applications for orphan medicinal product designation in 2002 to 85 Full implementation of the orphan drug legislation (Regulation (EC) No 141/ 2000) with new activities such as annual reports for designated products, follow-up and assessment of designation criteria at the time of application for marketing authorisation Increased activities in relation to the provision of information to patient organisations and interested parties (academia, health professionals and sponsors), including the publication of summaries of opinion at the time of the European Commission decision